Details for Patent: 9,006,256
✉ Email this page to a colleague
Which drugs does patent 9,006,256 protect, and when does it expire?
Patent 9,006,256 protects LENVIMA and is included in one NDA.
Protection for LENVIMA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fourteen patent family members in ten countries.
Summary for Patent: 9,006,256
| Title: | Antitumor agent for thyroid cancer |
| Abstract: | The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient. |
| Inventor(s): | Matsui; Junji (Tsukuba, JP) |
| Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
| Application Number: | 13/083,338 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,006,256 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,006,256
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,006,256
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2007252506 | ⤷ Sign Up | |||
| Canada | 2652442 | ⤷ Sign Up | |||
| China | 101443009 | ⤷ Sign Up | |||
| China | 104706637 | ⤷ Sign Up | |||
| European Patent Office | 2036557 | ⤷ Sign Up | |||
| Spain | 2556173 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
